Theravance Biopharma, Inc.

NASDAQ:TBPH

8.28 (USD) • At close November 1, 2024
Bedrijfsnaam Theravance Biopharma, Inc.
Symbool TBPH
Munteenheid USD
Prijs 8.28
Beurswaarde 405,074,988
Dividendpercentage 0%
52-weken bereik 7.44 - 11.71
Industrie Biotechnology
Sector Healthcare
CEO Mr. Rick E. Winningham M.B.A.
Website https://www.theravance.com

An error occurred while fetching data.

Over Theravance Biopharma, Inc.

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK)

Vergelijkbare Aandelen

Editas Medicine, Inc. logo

Editas Medicine, Inc.

EDIT

2.91 USD

Deciphera Pharmaceuticals, Inc. logo

Deciphera Pharmaceuticals, Inc.

DCPH

25.59 USD

Pulmonx Corporation logo

Pulmonx Corporation

LUNG

6.27 USD

Catalyst Pharmaceuticals, Inc. logo

Catalyst Pharmaceuticals, Inc.

CPRX

21.89 USD

IGM Biosciences, Inc. logo

IGM Biosciences, Inc.

IGMS

16.22 USD

Replimune Group, Inc. logo

Replimune Group, Inc.

REPL

11.9 USD

TG Therapeutics, Inc. logo

TG Therapeutics, Inc.

TGTX

26.9 USD

DocGo Inc. logo

DocGo Inc.

DCGO

3.63 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)